Mustang Bio, Inc., a biopharmaceutical company in Worcester, has a license agreement with Minnesota health nonprofit Mayo Clinic for new technology administering cancer treatment, Mustang said a press release Thursday.
The new technology developed by Mayo Clinic would make administration of CAR-T therapies more accessible and possibly lead to an off-the-shelf therapy, according to the announcement.
Chimeric antigen receptor T cells, known as CAR T cells, are genetically engineered T cells used in immunotherapy. CAR T cells can specifically target and destroy cancerous tumors.
“The potential use of this technology to facilitate how these treatments are delivered to patients can lead to earlier treatment post diagnosis, and using an off-the-shelf therapy may reduce the cost of care, all of which would help bring more innovative treatments to a broader base of patients in need,” said Manuel Litchman, president and CEO of Mustang, in a statement.
While the technology continues to be developed at Mayo Clinic, Mustang plans to file an investigational new drug application with the U.S. Food & Drug Administration for a clinical trial.
